Clinigen Group, through its Idis Global Access division, has signed three supply and distribution agreements. The new agreement with Mitsubishi Tanabe Pharma Europe (MTPE) builds on the current relationship to provide early access to argatroban where the product has no regulatory approval. Argatroban is indicated for anticoagulation in adult patients with heparin-induced thrombocytopenia type II (HIT) who require parenteral antithrombotic therapy. Under this new agreement, Idis GA will supply...